XM does not provide services to residents of the United States of America.

Teva Pharmaceutical raises 2024 outlook as Q3 profit beats estimates



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Teva Pharmaceutical raises 2024 outlook as Q3 profit beats estimates</title></head><body>

Adds details, updated 2024 outlook

JERUSALEM, Nov 6 (Reuters) -Teva Pharmaceutical Industries TEVA.TA raised its 2024 revenue and earnings guidance after beating third-quarter profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease.

The world's largest generic drugmaker said on Wednesday it earned 69 cents per diluted share excluding one-time items in the July-September quarter, up from 60 cents per share a year earlier. Revenue rose 13% to $4.33 billion.

Analysts had forecast earnings of 66 cents per share ex-items for the Israel-based company on revenue of $4.12 billion, LSEG I/B/E/S data showed.

Teva raised its 2024 revenue estimate to $16.1-16.5 billion from $16.0-16.4 billion, expecting higher sales from its Uzedy treatment of schizophrenia.

It now projects 2024 adjusted earnings per diluted share of $2.40-2.50, up from its previous estimate of $2.30-2.50.

U.S. sales of Uzedy rose to $35 million in the third quarter from $2 million a year earlier and were on track for $100 million in 2024.

Sales of migraine treatment Ajovy rose 4% to $58 million, while Huntington's disease drug Austedo jumped 28% to $435 million.

Generic drug sales in the United States climbed 30% to $1.09 billion, led by a copycat version of Revlimid that treats multiple myeloma.



Reporting by Steven Scheer; Editing by Louise Heavens and Mark Potter

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.